SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"22667395"
 

Sökning: onr:"22667395" > Long-term safety an...

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

Matikas, Alexios (författare)
Margolin, Sara (författare)
Hellström, Mats (författare)
visa fler...
Johansson, Hemming (författare)
Bengtsson, Nils-Olof (författare)
Karlsson, Lena (författare)
Edlund, Per (författare)
Karlsson, Per (författare)
Lidbrink, Elisabet (författare)
Linderholm, Barbro (författare)
Lindman, Henrik (författare)
Malmstrom, Per (författare)
Villman, Kenneth (författare)
Foukakis, Theodoros (författare)
Bergh, Jonas (författare)
visa färre...
 (utgivare)
SPRINGER 2018
2018
Engelska.
Ingår i: Breast Cancer Research and Treatment. - 0167-6806. ; 168:2, 349-355
  • swepub:Mat__t
Abstract Ämnesord
Stäng  
  • Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematologic nadirs. The SBG 2004-1 trial was a randomized feasibility phase II study which assessed tailored dose-dense epirubicin and cyclophosphamide (EC) followed by docetaxel (T) (group A), the same regimen with fixed doses (group B) and the TAC regimen (group C). Women aged 18-65 years, ECOG PS 0-1 with at least one positive axillary lymph node were randomized 1:1:1. The primary endpoint of the study was the safety and feasibility of the treatment. Toxicity was graded according to CTC-AE version 3.0. The design and short-term toxicity have been previously published. Here, we report safety and efficacy data after 10 years of follow-up. A total of 124 patients were included in the study. After a median follow-up of 10.3 years, the probability for 10-year survival was 78.5, 75.1, and 63.4% and for relapse free survival 64.1, 71.0, and 59.5% for groups A, B, and C, respectively. There were no cases of clinically diagnosed cardiotoxicity or hematologic malignancies. No patient was lost to follow-up. In this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10 years.

Ämnesord

Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Cancer and Oncology  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Cancer och onkologi  (hsv)

Nyckelord

Adjuvant chemotherapy
Breast cancer
Dose-dense
Randomized
Tailored dose

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy